Tuesday, October 19, 2021

Tag: leronlimab

CytoDyn Prepares Compelling Argument for Breakthrough Therapy Designation

CytoDyn Inc. (OTCMKTS: CYDY) released its Triple Negative Breast Cancer (TNBC) data in an 8-K filing last week, showcasing leronlimab’s extremely promising future in...

CytoDyn’s (CYDY) Long-Hauler Trial a Resounding Success: Clear Pathway to Approval...

Clinically Significant Data in 18 of 24 SymptomsSeeking Breakthrough Therapy Designation in Long-Haulers and CancerDefinitive timeline for HIV BLA Filing by October 2021Dosing of...

CytoDyn (CYDY) Conference Call Roundup

After an FDA statement on Monday May 17th, 2021, CytoDyn Inc. (OTCMKTS: CYDY) was indirectly forced to publicly respond to it.  The FDA statement...